Opgevolgde bedrijven

  • As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis and other inflammatory diseases (ABX464), HIV (ABX464), and liver cancer (ABX196).
  • Abivax’ mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
  • Commercially driven hospital pharmaceutical group focused on the development andcommercialisation of new nausea and vomiting treatments for surgical and cancer patients.
  • Two product candidates based on the same active ingredient, amisulpride (repurposed drug):Barhemsi and APD403
  •  Advicenne specializes in the research and development of drugs for the treatment of neglected neurological and nephrological diseases, mostly among children.
  • Modular and versatile ROCK® (Redirected Optimized Cell Killing) platform
  • Proprietary, next-generation bispecific antibodies
  • Petravalent (four binding sites) bispecific (two targets) immune cell engagers have the ability to bring NK cells or T cells into proximity to cancer cells and trigger a signal cascade that leads to the destruction these cancer cells.
  • Argenx combines the diversity of the llama immune system with antibody engineering advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases.
  • The platforms allow to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect
  • Biocartis develops fully automated molecular diagnostics for the own Idylla platform, a revolutionary, fully-automated, real-time PCR based molecular testing system.
  • Designed to offer results in a minimum amount of time, it makes molecular testing fast, convenient and suitable for any lab in oncology, pathology and for pharma (high accuracy and reproducibility, actionable in 1 day, minimal sample need)
  • BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.
  • Its cutting-edge pipeline includes individualized mRNA-based product candidates, innovative chimeric antigen receptor T cells, novel checkpoint immunomodulators, targeted cancer antibodies and small molecules.
  • BioNTech has established relationships with seven pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant and Pfizer, and has published over 150 peer-reviewed publications on its scientific approach.
  • Bone Therapeutics is an advanced biotechnology company with a unique approach (using differentiated bone-forming cells administered via a minimally invasive procedure) to the development of cell therapy products for orthopaedics and bone diseases.
  • Bone Therapeutics has developed an allogeneic off-the-shelf cell therapy platform, ALLOB, and an enhanced viscosupplement, JTA-004, which target 3 bone indications and offer the potential for additional product extensions.
  • Clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.
  • Frans bedrijf dat zich gespecialiseerd heeft in voedselallergies (peanuts en koemelk) en bestrijdt deze met een “patch”.
  • Viaskin technology
  • de bedrijfswaarde (EV) is 621M en de handel is levendig met een gemiddelde dagomzet van €10M
  • Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action.
  • Filgotinib, Galapagos’ most advanced novel mode-of-action program is being developed by Gilead and Galapagos in several inflammatory indications.
  • Galapagos is progressing multiple programs in inflammation, cystic fibrosis, metabolic diseases, fibrosis, and other disease areas.
  • late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases.
  • Elafibranor (GFT505) is GENFIT’s lead pipeline product for the treatment of NASH (Non- Alcoholic Steato-Hepatitis)
  • Belangrijk Zwitsers bedrijf (ca 750 werknemers) dat de bedoeling heeft kleine organische moleculen te
    ontdekken/ontwikkelen in de strijd tegen een reeks van uiteenlopende ziekten: Resistente hyperthensie, Lupus, Slapeloosheid, Cerebrale vaspasme (hersenbloeding), de ziekte van Fabry.
  • Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.
  • Clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology
  • Advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.
  • Building a fully integrated biopharmaceutical company to maximize the potential of ATIR, our proprietary cell-based immunotherapy platform.
  • ATIR101; treatment of acute leukemia and ATIR201 (ph.3) ; treatment of thalassemia (ON HOLD)
  • Take over (to be approuved by the share holders) of the USA based CytoSen Therapeutics who developed a proprietary natural killer (NK)-cell platform to enable NK-cell therapy with broad anti-cancer potential.
  • A biopharmaceutical company focused on bispecific antibodies that target cancer (stem) cells, enhance tumor immunity or modulate the tumor micro-environment.
  • Main technologies: MeMo transgenic mouse for human antibodies, Biclonics® Platform (full length IgG human bispecific antibodies for functional screening, reliable manufacturing and predictable behavior in patients).
  • Mithra is dedicated to providing innovation and choice in women’s health, with a particular focus on contraception and menopause.
  • Mithra’s two lead development candidates – a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta® – are built on Mithra’s unique natural estrogen platform, E4 (Estetrol).
  • Central to Molecular Partners business is the proprietary DARPin® platform. Multi-DARPin® drug candidates are built from DARPin® protein modules. These modules are single-domain proteins, one-tenth the size of a full antibody, with a constant framework and a randomized target binding surface.
  • Current pipeline focuses on oncology (in-house), immuno-oncology (Amgen) and ophtalmology (Allergan). Furthest evolved programs are MP0250 in phase 2 in multiple myeloma and NSCLC, and Abicipar in Phase 3 in wet AMD.
  • Note: the capabilities of this platform are largely similar to the Ablynx Nanobody platform, in terms of generating multi-specific therapeutics, high affinity, tuneable half-life, difficult tarets, etc. Nervertheless, the market cap is still mid-size for biotech and the partnerships remain limited (Amgen and Allergan).
  • German biotech company, antibody drug discovery and development, focus is on cancer
  • Tremfya® (guselkumab) is a fully human anti-interleukin (IL)-23 monoclonal antibody developed by Janssen (HuCAL antibody library technology was used to generate the guselkumab antibody under license from MorphoSys)
  • Paradepaardje: MOR208
  • Late stage clinical company pioneering nanomedicine
  • CE markering verkregen voor soft tissue sarcoma (STS) na succesvol proof-of-concept in Phase III clinical trial (Juni 2018)
  • Oncodesign is a company with a mixed activity profile, active in biotech environment: 1) service provider for integrated drug discovery (both in vitro and in vivo); 2) engaging longterm partnerships based on in-house research (kinase inhibitor, technology, …); 3) licensing arrangements of internal portfolio (technologies, drug candidates and radiotracers, …).
  • Therapeutic areas and experimental models include cancer, (immuno-)oncology, inflammation, liver, etc…
  • Oncodesign’s capital is primarily in the hands of its top management (50%), including Dr. Philippe Genne, CEO and founder.
  • Treatments to preserve vision for patients with diseases affecting the back of the eye
  • A diverse portfolio of disease-modifying drug candidates, including treatments for diabetic eye disease, a leading cause of blindness in people of working age worldwide.
  • Global rights to Jetrea (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the U.S.) and vitreomacular traction (outside the U.S.).
  • Oncurious, joint venture with VIB, for cancer treatment
  • Poxel is a biopharmaceutical company that specializes in the development of medicines for the treatment of metabolic diseases, primarily type II diabetes.
  • The group has a portfolio of 2 products in clinical development, including 1 in Phase II (Imeglimin for the treatment of type II diabetes and its associated pathologies) and 1 in phase I (the PXL770, for the treatment of glucose and lipid irregularities), along with 4 products in research phase.
  • RNA therapies, a technology that allows to address inherited diseases that are caused by a genetic defect
  • Focus is on diseases that are very severe or life threatening, and have limited treatment options
  • French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer and infectious diseases.
  • Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.
  • The company’s three lead clinical-stage programs are: TG4010 for non-small cell lung cancer, TG4001 for HPV positive cancers and Pexa-Vec for liver cancer.
  • Uniqure is a gene therapy company originally founded in The Netherlands.
  • Uniqure has a pipeline of adeno associated virus (AAV) – based gene therapy. Uniqure is currently conducting a pivotal phase 3 trial in the lead indication, hemophilia B, and has established preclinical proof-of-concept in Huntington’s disease
  • Danish biotech, engaged in discovery and development of peptide based medicines (diabetes/metabolic diseases)
  • Portfolio of medicines in late-stage development
  • 2 drugs on the market (Lixisenatide (license sold) and Soliqua)